Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 8, Issue 1, 2010, Pages 23-28

  Sartor, Oliver ^a   Halstead, Michael ^a   Katz, Leah ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cabazitaxel; Docetaxel; Hormone refractory; TROPIC

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

CANCER PAIN; CANCER SURVIVAL; CASTRATE RESISTANT PROSTATE CANCER; DRUG APPROVAL; DRUG EXCRETION; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

EID: 78651107389     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.3816/CGC.2010.n.004     Document Type: Review

References (12)

1. Sartor O, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). 2010 Genitourinary Cancers Symposium, Abstract 9.
2. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376:1147-54.
3. US Food and Drug Administration (FDA) cabazitaxel package insert. Available at:
4. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009; 27:5431-8.
5. Bissery M-C, Bouchard H, Riou JF, et al. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res 2000; 41: 214 (abstract 1364).
6. Sanofi-aventis. XRP6258 investigator's brochure. Antony (France): Sanofi-aventis; 2000.
7. Bates SF, Chen C, Robey R, et al. Reversal of multidrug resistance: Lessons from clinical oncology. Novartis Found Symp 2002; 243:83-96.
8. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-30.
9. Sanofi-aventis: Data on file.
10. Tannock IF, de Wit R, Berry WR, et al, On behalf of the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12.
11. De Bono JS, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). J Clin Oncol 2010; 28(15 suppl):344s (abstract 4508).
12. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120:2715-30.